ATRS Antares Pharma Inc.

3.22
+0.01  (+0%)
Previous Close 3.21
Open 3.21
Price To Book 21.47
Market Cap 507282886
Shares 157,541,269
Volume 497,545
Short Ratio
Av. Daily Volume 789,319

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved December 8, 2011.
Anturol
Overactive bladder
Approved Oct 14, 2013.
OTREXUP
Rheumatoid arthritis (RA)
Approval announced February 14, 2018.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy
FDA Approval announced October 1, 2018.
XYOSTED (testosterone enanthate)
Testosterone deficiency

Latest News

  1. Antares Pharma, Inc. (NASDAQ:ATRS): Time For A Financial Health Check
  2. What Kind Of Shareholder Appears On The Antares Pharma, Inc.’s (NASDAQ:ATRS) Shareholder Register?
  3. Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors
  4. ATRS: Xyosted & Epi Pen Available for Sale
  5. Should You Buy NanoString Technologies Inc (NSTG)?
  6. Is Noodles & Co (NDLS) A Good Stock To Buy?
  7. Factors of Influence in 2018, Key Indicators and Opportunity within Antares Pharma, Encana, PPG Industries, Cato, Cimarex Energy, and Ormat Technologies — New Research Emphasizes Economic Growth
  8. Antares Pharma Announces the Commercial Availability of XYOSTED™ (Testosterone Enanthate) Injection — A New Treatment for Adult Men Diagnosed With Testosterone Deficiency
  9. Teva (TEVA) Launches First Generic Version of Mylan's EpiPen
  10. Teva's generic EpiPen hits the market in limited doses
  11. Antares Pharma Partner Teva Announces Commercial Availability of Generic Epipen®
  12. ATRS: Xyosted Launch Before Year End
  13. Antares Pharma to Present at the 30th Annual Piper Jaffray Healthcare Conference
  14. Edited Transcript of ATRS earnings conference call or presentation 6-Nov-18 1:30pm GMT
  15. Healthcare Value Capital, LLC Buys Antares Pharma Inc, Sells Novelion Therapeutics Inc
  16. Robbins Arroyo LLP: Antares Pharma, Inc. (ATRS) Misled Shareholders According to Class Action
  17. Antares Pharma: 3Q Earnings Snapshot

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 19608607
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604649
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19561998
  4. 8-K - Current report 19512133
  5. 8-K - Current report 181232383
  6. 8-K - Current report 181185936
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163564
  8. 8-K - Current report 181161452
  9. 8-K - Current report 181099553
  10. 8-K - Current report 181057514